Precision BioSciences, Inc.
Clinical trials sponsored by Precision BioSciences, Inc., explained in plain language.
A clinical-stage biotech developing gene editing therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Gene therapy takes on hepatitis b: first human trial launches Results expected Dec 2026 (estimated)
-
Gene therapy takes on hepatitis b: first human trial launches
Disease control Recruiting nowThis early-stage study tests a new gene therapy called PBGENE-HBV in 45 adults with chronic hepatitis B who are already on antiviral medication. The goal is to see if the treatment is safe and can help control the virus. Participants must be in good health and have no liver scarr…
Phase 1 • Sponsor: Precision BioSciences, Inc. • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Gene editing trial hopes to fix duchenne muscular dystrophy at its source
Disease control Recruiting nowThis early-stage study tests a new gene-editing medicine called PBGENE-DMD in 18 boys aged 2 to 7 with Duchenne muscular dystrophy. The treatment aims to correct the genetic mistake that causes the disease, potentially restoring muscle strength. Researchers are first checking if …
Phase 1/2 • Sponsor: Precision BioSciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC